Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

16 Feb 2012 07:00

RNS Number : 5149X
Intercede Group PLC
16 February 2012
 



16 February 2012

Intercede Group plc

("Intercede")

 

Trading Update

 

Intercede reports that the financial year ending 31 March 2012 will be profitable and cash generating. However, with six weeks to go before the end of the period, the order book of £6.3m stands at a similar position to the prior year. The Company's ability to book further orders before 31 March is dependent on a small number of projects in the pipeline receiving customer approval in sufficient time for deliveries to be made and revenue recognised.

In a challenging global economy, customers are moving to rental models that defer revenue recognition into future periods (with the potential to generate much higher medium term shareholder value from greater earnings visibility) and/or deferring project start dates. A number of large prospects have transitioned within the last six months from wishing to buy perpetual software licenses to specifying rental models, driven by market trends for Software as a Service (SaaS),at the expense of reducing current year revenue expectations. We continue to invest for growth as ID and Credentials Management remains a key priority for governments and enterprise. We see a continuing global pipeline of opportunities, which may be delayed, but not cancelled.

As at 10 February 2012 cash balances totalled £7.0m up from £6.6m reported on 30 September 2011.

Richard Parris, Intercede Chairman & Chief Executive, said:

"Whilst it is disappointing that short term revenues do not reflect the significant strategic and commercial progress made by Intercede, we nevertheless believe the business is in a better position to generate long term shareholder value. We are continuing to work to address any revenue gap in the current year but we are dependent on the buying behaviour of large government and corporate customers.

"In the period we have invested according to plan to reinforce our positioning with major partners such as Microsoft, extended our product reach into the smart phone market and are poised to participate in a number of high volume managed service projects.

"To fully exploit the growth opportunity we have created, Intercede has also appointed an international sales director, increased our marketing expenditure, invested in a new website, engaged with UKTI to drive export sales into new markets and extended our US office.

"We will issue a further update on trading in early April."

###

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. + 44 (0)20 7220 0500

Sarah Wharry

Rose Herbert

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

Clare Gilbey

 

About Intercede

Intercede is the producer of the MyID® identity and credential management system (IDCMS), the MyID Management Agent for Microsoft® Forefront™ Identity Manager and a range of mobile applications for securing smartphones.

The company's website has recently been re-launched to better reflect its enhanced proposition. For more information visit www.intercede.com, email info@intercede.com or call +44 (0)1455 558111.

MyID technology is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 14 federal agencies, two million smart cards in support of the US Transportation Worker Identity Credential program (TWIC), four US financial institutions and 340,000 smart corporate identity badges for Boeing, Booz Allen Hamilton and Lockheed Martin. In Europe, Australasia and the Middle East, MyID is being deployed in support of government identity, financial services, healthcare and corporate employee ID security projects.

MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people, secure devices and their associated credentials within a single, integrated, workflow driven platform. This includes enabling and managing secure registration, biometric capture, application vetting and approval through to smart card and smartphone personalization, issuance and management.

At the forefront of the secure identity field, Intercede also offers innovative new solutions for smartphones, including secure email, physical and logical access, identity verification via near field communications and attribute management. With the trend towards 'bring your own device' in the workplace and the move to cloud-based services, MyID allows organizations to embrace new and more convenient approaches to security.

MyID was the first electronic personalization product to achieve compliance with the US FIPS-201 Personal Identity Verification (PIV) standard and is widely deployed by federal agencies, government contractors and other commercial entities. In particular, it supports the latest standards applicable for all PIV, PIV-Interoperable and PIV-Compatible (CIV) deployments.

MyID provides customers with a platform that can meet their needs now and in the future. It is a fully supported commercial off-the-shelf product that can be quickly deployed for thousands or millions of users.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSFUFWIFESEIE
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.